Advertisement
China’s Akeso, dubbed biotech’s DeepSeek, gets share boost on cancer-drug trial data
Lung-cancer drug ivonescimab is ‘potentially two to three years ahead of competitors’, analyst says
3-MIN READ3-MIN
1
Listen
Shares of Chinese drug firm Akeso – likened by some Western media outlets to artificial intelligence start-up DeepSeek – rose after the company unveiled clinical-trial data showing that its lung-cancer drug outperformed a highly effective existing treatment.
The data showed that ivonescimab had “a decisive and strong positive outcome with both significant and clinically meaningful benefits”, Akeso said in a filing with the Hong Kong stock exchange on Monday. The drug, used along with chemotherapy, “substantially extended” survival for patients with squamous non-small-cell lung cancer, compared with rival BeOne Medicine’s tislelizumab plus chemotherapy, it said.
BeOne launched tislelizumab in late 2019 after receiving initial approval in China. Approved in the European Union in 2023 and in the US last year, the drug recorded US$1.74 billion in sales in the first half. BeOne has most of its operations in China and the US.
Akeso’s trial data was presented by Lu Shen, director of oncology at Shanghai Chest Hospital, at the European Society For Medical Oncology presidential symposium in Berlin. It was also published in peer-reviewed medical journal The Lancet.
Select Voice
Select Speed
1x
AI-generated voice